Pharmaceuticals

Global Systemic Amyloidosis Therapeutic Market Report 2026–2030: Data-Driven Growth Insights

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the systemic amyloidosis therapeutic market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Systemic Amyloidosis Therapeutic Market be in 2030 compared with 2026?

The systemic amyloidosis therapeutic market size has seen robust growth in recent years. This market is expected to expand from $5.67 billion in 2025 to $6.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The historical expansion of this market can be attributed to several factors, including the past underdiagnosis of amyloidosis, a prevalent reliance on chemotherapy regimens, an increase in hematology treatment centers, enhanced rare disease awareness, and the early adoption of proteasome inhibitors.

The systemic amyloidosis therapeutic market size is poised for significant expansion over the next few years. It is forecast to grow to $8.88 billion in 2030, achieving a compound annual growth rate (CAGR) of 9.4%. The impetus behind this growth during the forecast period stems from escalating rare disease diagnosis rates, the proliferation of targeted biologic drugs, increasing approvals for gene silencing therapies, the expansion of specialty clinic networks, and more robust orphan drug incentives. Prominent trends anticipated in the forecast period involve targeted amyloid protein stabilizer drugs, gene silencing amyloidosis therapies, treatments utilizing monoclonal antibodies, combination regimen treatment protocols, and organ-specific supportive drug strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33337&type=smp

What Drivers Are Guiding Growth Patterns In The Systemic Amyloidosis Therapeutic Market?

The increasing integration of personalized medicine techniques is anticipated to fuel expansion within the systemic amyloidosis therapeutic market in the future. This medical strategy tailors treatment and prevention plans specifically to an individual’s genetic makeup, biological markers, and distinct disease attributes. Demand for such customized medicine is escalating, driven by advancements in genomic and biomarker technologies. These innovations enable healthcare professionals to accurately pinpoint disease causes and customize therapies, thereby enhancing effectiveness and minimizing side effects for individual patients. The increasing use of personalized medicine boosts the need for systemic amyloidosis therapeutics because systemic amyloidosis patients exhibit diverse amyloid subtypes (e.g., AL, ATTR) and genetic differences, necessitating treatments precisely engineered to address their individual disease profiles for optimal efficacy and fewer adverse reactions. For example, data from April 2025, provided by the Personalized Medicine Coalition (PMC), a US-based nonprofit advocacy and educational organization, indicated that in 2023, the FDA sanctioned 16 novel personalized treatments for rare disease patients, an increase from six in 2022. Consequently, the expanding adoption of personalized medicine approaches is a key factor propelling the growth of the systemic amyloidosis therapeutic market.

How Is The Systemic Amyloidosis Therapeutic Market Divided Into Segments?

The systemic amyloidosis therapeutic market covered in this report is segmented –

1) By Product Type: Small Molecule Drugs; Biologic Therapies; Monoclonal Antibodies; Chemotherapy Based Regimens; Targeted Therapies; Supportive Treatments

2) By Formulation: Tablets; Capsules; Injection

3) By Route of Administration: Oral; Intravenous; Subcutaneous

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

5) By End User: Hospitals; Specialty Clinics; Specialty Pharmacies; Research and Academic Institutes; Other End Users

Subsegments:

1) By Small Molecule Drugs: Proteasome Inhibitors; Stabilizers of Transthyretin Protein; Amyloid Fibril Disruptors; Immunomodulatory Small Molecules

2) By Biologic Therapies: Recombinant Protein Therapies; Gene Silencing Biologic Agents; Plasma Derived Biologic Products

3) By Monoclonal Antibodies: Anti Amyloid Fibril Antibodies; Anti Light Chain Antibodies; Targeted Clearance Antibodies

4) By Chemotherapy Based Regimens: Alkylating Agent Based Regimens; Proteasome Inhibitor Based Chemotherapy; Combination Chemotherapy Protocols

5) By Targeted Therapies: Targeted Light Chain Suppression Therapies; Targeted Transthyretin Reduction Therapies; Organ Specific Targeted Treatments

6) By Supportive Treatments: Cardiac Supportive Therapies; Renal Supportive Therapies; Neurological Symptom Management Therapies; Nutritional and Palliative Care Therapies

Which Trends Are Influencing The Development Of The Systemic Amyloidosis Therapeutic Market?

Key companies within the systemic amyloidosis therapeutic market are increasingly concentrating on the development of advanced, targeted treatment approaches, such as those leveraging RNA interference, to tackle the fundamental genetic origins of protein misfolding conditions, slow down disease progression, and enhance long-term patient outcomes. RNA interference-based therapies function by specifically deactivating disease-causing genes, thereby decreasing the creation of detrimental proteins responsible for systemic organ damage. An illustrative example of this progress is the introduction of AMVUTTRA by Alnylam Pharmaceuticals, a US-based biotechnology firm, in March 2025. AMVUTTRA provides a precise, disease-modifying treatment for adults diagnosed with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This therapeutic, developed by Alnylam Pharmaceuticals, stands as the first RNAI treatment proven to mitigate cardiovascular mortality, reduce hospital admissions, and lessen urgent heart failure visits among this patient group. AMVUTTRA operates by swiftly inhibiting transthyretin production at its origin, thereby addressing the root cause of amyloid deposition. Its benefits are consistently observed across various aspects, including cardiovascular health outcomes, physical capabilities, and overall quality of life.

Which Key Players Are Driving Competition In The Systemic Amyloidosis Therapeutic Market?

Major companies operating in the systemic amyloidosis therapeutic market are Johnson & Johnson Services Inc., Sanofi SA, Novartis Plc, AstraZeneca Plc, GSK Plc, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals, Arcturus Therapeutics Inc, Prothena Biosciences, Fortress Biotech Inc., Intellia Therapeutics Inc., Zentalis Pharmaceuticals Inc., BridgeBio Pharma Inc., Neurimmune AG, HaemaLogix Pty Ltd., Attralus Inc., and Oncopeptides AB.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/systemic-amyloidosis-therapeutic-market-report

Which Region Is Projected To Lead The Systemic Amyloidosis Therapeutic Market During The Forecast Period?

North America was the largest region in the systemic amyloidosis therapeutic market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic amyloidosis therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Systemic Amyloidosis Therapeutic Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33337&type=smp

Browse Through More Reports Similar to the Global Systemic Amyloidosis Therapeutic Market 2026, By The Business Research Company

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Atrophic Glossitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/atrophic-glossitis-treatment-global-market-report

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795